Answers are grounded in this paper and cite their sources.
Background/Objectives: The impact of SARS-CoV-2 infection on the metabolic presentation and early course of type 1 diabetes mellitus (T1DM) in children remains incompletely understood. Although an increased frequency of diabetic ketoacidosis (DKA) has been reported during the coronavirus disease 2019 (COVID-19) pandemic, it is unclear whether this reflects a direct pathogenic role of the virus or indirect effects related to healthcare access and delayed presentation. Methods: This retrospective study included children with newly diagnosed T1DM evaluated between 2021 and 2025 at a single tertiary pediatric center. Two cohorts were compared: patients with PCR-documented and serologically confirmed prior SARS-CoV-2 infection (nucleocapsid antibody-based assay) and those without. DKA severity, acid-base parameters, lipid profile, autoimmune markers, thyroid function, and metabolic indices were compared at diagnosis. HbA1c, insulin dose, and C-peptide were assessed at diagnosis and 12-month follow-up. Multivariable regression, interaction testing, sensitivity, and subgroup analyses were performed. Results: Of 134 children, 58 had confirmed prior SARS-CoV-2 infection. Median HbA1c at diagnosis was 11.02% in the COVID group versus 11.77% in the non-COVID group (p = 0.057). Insulin requirements were similar (p = 0.87). Severe DKA occurred in 39.7% versus 42.1% (p = 0.90). C-peptide levels at diagnosis and 12 months did not differ between groups. Prior SARS-CoV-2 infection was not significantly associated with HbA1c at diagnosis (β = −0.65% HbA1c, 95% CI −1.33 to 0.03; p = 0.061; additionally adjusted for DKA grade, β = −0.68%, p = 0.079). HbA1c at 12 months was similar between groups (p = 0.85); in multivariable analysis adjusted for baseline HbA1c, age, and sex, prior infection was not significantly associated with HbA1c at follow-up (adjusted β = 0.39%, 95% CI −0.06 to 0.84; p = 0.092). Conclusions: No statistically significant association was found between confirmed prior SARS-CoV-2 infection and metabolic severity at diagnosis or glycemic outcomes during the first year, although the HbA1c comparison approached significance and the sample size limited power to detect differences smaller than approximately 1.04% HbA1c. The findings do not exclude a modest effect of prior infection, and larger prospective studies are warranted.
No takes yet. Share an insight, caveat, or question.
Basaca et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: